{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:04:50Z","timestamp":1788865490907,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-18383-2","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:49:42Z","timestamp":1758887382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["FAERS based disproportionality analysis and network pharmacology investigation of doxorubicin associated drug induced cardiotoxicity"],"prefix":"10.1038","volume":"15","author":[{"given":"Jing","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuohui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"18383_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119527","volume":"278","author":"S Sritharan","year":"2021","unstructured":"Sritharan, S. & Sivalingam, N. A comprehensive review on time-tested anticancer drug doxorubicin. Life Sci. 278, 119527 (2021).","journal-title":"Life Sci."},{"key":"18383_CR2","first-page":"4478","volume":"27","author":"S Peter","year":"2022","unstructured":"Peter, S., Alven, S., Maseko, R. B. & Aderibigbe, B. A. Doxorubicin-based hybrid compounds as potential anticancer agents: A review. Mol. Basel Switz. 27, 4478 (2022).","journal-title":"Mol. Basel Switz."},{"key":"18383_CR3","doi-asserted-by":"publisher","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"DD Von Hoff","year":"1979","unstructured":"Von Hoff, D. D. et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91, 710\u2013717 (1979).","journal-title":"Ann. Intern. Med."},{"key":"18383_CR4","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.3390\/ijms23031912","volume":"23","author":"BB Wu","year":"2022","unstructured":"Wu, B. B., Leung, K. T. & Poon, E.N.-Y. Mitochondrial-targeted therapy for doxorubicin-induced cardiotoxicity. Int. J. Mol. Sci. 23, 1912 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"18383_CR5","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1158\/1078-0432.CCR-20-4592","volume":"27","author":"RL Jones","year":"2021","unstructured":"Jones, R. L. et al. Prospective evaluation of doxorubicin cardiotoxicity in patients with advanced soft-tissue sarcoma treated in the ANNOUNCE phase III randomized trial. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 27, 3861\u20133866 (2021).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"18383_CR6","doi-asserted-by":"publisher","first-page":"454","DOI":"10.2174\/0113894501290296240327081624","volume":"25","author":"R Morris","year":"2024","unstructured":"Morris, R., Ali, R. & Cheng, F. Drug repurposing using FDA adverse event reporting system (FAERS) database. Curr. Drug Targets 25, 454\u2013464 (2024).","journal-title":"Curr. Drug Targets"},{"key":"18383_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185654","volume":"12","author":"A Fukuda","year":"2017","unstructured":"Fukuda, A. et al. Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system. PLoS ONE 12, e0185654 (2017).","journal-title":"PLoS ONE"},{"key":"18383_CR8","doi-asserted-by":"publisher","first-page":"760","DOI":"10.7150\/ijbs.65258","volume":"18","author":"CY Kong","year":"2022","unstructured":"Kong, C. Y. et al. Underlying the mechanisms of doxorubicin-Induced acute cardiotoxicity: Oxidative stress and cell death. Int. J. Biol. Sci. 18, 760\u2013770 (2022).","journal-title":"Int. J. Biol. Sci."},{"key":"18383_CR9","doi-asserted-by":"publisher","first-page":"15137","DOI":"10.1038\/s41598-025-99669-3","volume":"15","author":"Y Cheng","year":"2025","unstructured":"Cheng, Y. et al. FAERS based disproportionality analysis and network pharmacology investigation of taxanes associated drug induced liver injury. Sci. Rep. 15, 15137 (2025).","journal-title":"Sci. Rep."},{"key":"18383_CR10","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.1038\/s41598-024-55185-4","volume":"14","author":"H Su","year":"2024","unstructured":"Su, H., Jia, J., Mao, Y., Zhu, R. & Li, Z. A real-world analysis of FDA adverse event reporting system (FAERS) events for liposomal and conventional doxorubicins. Sci. Rep. 14, 5095 (2024).","journal-title":"Sci. Rep."},{"key":"18383_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"MER O\u2019Brien","year":"2004","unstructured":"O\u2019Brien, M. E. R. et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 15, 440\u2013449 (2004).","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"18383_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133569","volume":"10","author":"M Xing","year":"2015","unstructured":"Xing, M., Yan, F., Yu, S. & Shen, P. Efficacy and cardiotoxicity of liposomal doxorubicin-based chemotherapy in advanced breast cancer: a meta-analysis of ten randomized controlled trials. PLoS ONE 10, e0133569 (2015).","journal-title":"PLoS ONE"},{"key":"18383_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3109\/10611869609015970","volume":"4","author":"PG Tardi","year":"1996","unstructured":"Tardi, P. G., Boman, N. L. & Cullis, P. R. Liposomal doxorubicin. J. Drug Target. 4, 129\u2013140 (1996).","journal-title":"J. Drug Target."},{"key":"18383_CR14","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1002\/cncr.20207","volume":"100","author":"M Theodoulou","year":"2004","unstructured":"Theodoulou, M. & Hudis, C. Cardiac profiles of liposomal anthracyclines: Greater cardiac safety versus conventional doxorubicin?. Cancer 100, 2052\u20132063 (2004).","journal-title":"Cancer"},{"key":"18383_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113903","volume":"156","author":"Y Chen","year":"2022","unstructured":"Chen, Y., Shi, S. & Dai, Y. Research progress of therapeutic drugs for doxorubicin-induced cardiomyopathy. Biomed. Pharmacother. Biomedecine Pharmacother. 156, 113903 (2022).","journal-title":"Biomed. Pharmacother. Biomedecine Pharmacother."},{"key":"18383_CR16","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3390\/biology12071031","volume":"12","author":"AI Afonso","year":"2023","unstructured":"Afonso, A. I., Amaro-Leal, \u00c2., Machado, F., Rocha, I. & Geraldes, V. Doxorubicin dose-dependent impact on physiological balance-a holistic approach in a rat model. Biology 12, 1031 (2023).","journal-title":"Biology"},{"key":"18383_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12012-017-9411-5","volume":"18","author":"M Ahmadian","year":"2018","unstructured":"Ahmadian, M. & Dabidi Roshan, V. Modulatory effect of aerobic exercise training on doxorubicin-induced cardiotoxicity in rats with different ages. Cardiovasc. Toxicol. 18, 33\u201342 (2018).","journal-title":"Cardiovasc. Toxicol."},{"key":"18383_CR18","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2013.55.0459","volume":"32","author":"MK Accordino","year":"2014","unstructured":"Accordino, M. K., Neugut, A. I. & Hershman, D. L. Cardiac effects of anticancer therapy in the elderly. J. Clin. Oncol. 32, 2654\u20132661 (2014).","journal-title":"J. Clin. Oncol."},{"key":"18383_CR19","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1200\/JCO.2005.12.121","volume":"23","author":"SE Lipshultz","year":"2005","unstructured":"Lipshultz, S. E. et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 23, 2629\u20132636 (2005).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"18383_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b4606","volume":"339","author":"DA Mulrooney","year":"2009","unstructured":"Mulrooney, D. A. et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the childhood cancer survivor study cohort. BMJ 339, b4606 (2009).","journal-title":"BMJ"},{"key":"18383_CR21","volume":"50","author":"C Belger","year":"2024","unstructured":"Belger, C., Abrahams, C., Imamdin, A. & Lecour, S. Doxorubicin-induced cardiotoxicity and risk factors. Int. J. Cardiol. Heart Vasc. 50, 101332 (2024).","journal-title":"Int. J. Cardiol. Heart Vasc."},{"key":"18383_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.taap.2016.09.012","volume":"310","author":"GR Jenkins","year":"2016","unstructured":"Jenkins, G. R. et al. Sex-related differential susceptibility to doxorubicin-induced cardiotoxicity in B6C3F1 mice. Toxicol. Appl. Pharmacol. 310, 159\u2013174 (2016).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"18383_CR23","first-page":"4","volume":"2","author":"BN Zordoky","year":"2016","unstructured":"Zordoky, B. N. et al. The interplay between genetic background and sexual dimorphism of doxorubicin-induced cardiotoxicity. Cardio-Oncol. Lond. Engl. 2, 4 (2016).","journal-title":"Cardio-Oncol. Lond. Engl."},{"key":"18383_CR24","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S1470-2045(10)70204-7","volume":"11","author":"SE Lipshultz","year":"2010","unstructured":"Lipshultz, S. E. et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: Long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 11, 950\u2013961 (2010).","journal-title":"Lancet Oncol."},{"key":"18383_CR25","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.amjcard.2015.04.064","volume":"116","author":"L Wang","year":"2015","unstructured":"Wang, L. et al. Major cardiac events and the value of echocardiographic evaluation in patients receiving anthracycline-based chemotherapy. Am. J. Cardiol. 116, 442\u2013446 (2015).","journal-title":"Am. J. Cardiol."},{"key":"18383_CR26","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41420-019-0182-6","volume":"5","author":"KM McSweeney","year":"2019","unstructured":"McSweeney, K. M., Bozza, W. P., Alterovitz, W.-L. & Zhang, B. Transcriptomic profiling reveals p53 as a key regulator of doxorubicin-induced cardiotoxicity. Cell Death Discov. 5, 102 (2019).","journal-title":"Cell Death Discov."},{"key":"18383_CR27","doi-asserted-by":"publisher","first-page":"19626","DOI":"10.1073\/pnas.1904979116","volume":"116","author":"J Li","year":"2019","unstructured":"Li, J. et al. p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities. Proc. Natl. Acad. Sci. U. S. A. 116, 19626\u201319634 (2019).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"80","key":"18383_CR28","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1161\/HYPERTENSIONAHA.123.21427","volume":"1979","author":"A Liu","year":"2023","unstructured":"Liu, A. et al. ESCRT-III Component CHMP4C attenuates cardiac hypertrophy by targeting the Endo-Lysosomal Degradation of EGFR. Hypertens. Dallas Tex 1979(80), 2674\u20132686 (2023).","journal-title":"Hypertens. Dallas Tex"},{"key":"18383_CR29","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/labinvest.2014.95","volume":"94","author":"L Ma","year":"2014","unstructured":"Ma, L., Kerr, B. A., Naga Prasad, S. V., Byzova, T. V. & Somanath, P. R. Differential effects of Akt1 signaling on short- versus long-term consequences of myocardial infarction and reperfusion injury. Lab. Investig. J. Tech. Methods Pathol. 94, 1083\u20131091 (2014).","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"key":"18383_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08945-9","author":"S Cho","year":"2025","unstructured":"Cho, S. et al. Selective inhibition of stromal mechanosensing suppresses cardiac fibrosis. Nature https:\/\/doi.org\/10.1038\/s41586-025-08945-9 (2025).","journal-title":"Nature"},{"key":"18383_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.taap.2018.04.009","volume":"348","author":"T Cunha-Oliveira","year":"2018","unstructured":"Cunha-Oliveira, T., Ferreira, L. L., Coelho, A. R., Deus, C. M. & Oliveira, P. J. Doxorubicin triggers bioenergetic failure and p53 activation in mouse stem cell-derived cardiomyocytes. Toxicol. Appl. Pharmacol. 348, 1\u201313 (2018).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"18383_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109751","volume":"123","author":"L Zhang","year":"2020","unstructured":"Zhang, L., Liu, L. & Li, X. MiR-526b-3p mediates doxorubicin-induced cardiotoxicity by targeting STAT3 to inactivate VEGFA. Biomed. Pharmacother. Biomedecine Pharmacother. 123, 109751 (2020).","journal-title":"Biomed. Pharmacother. Biomedecine Pharmacother."},{"key":"18383_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2022.147001","volume":"851","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. Low expression of ESR1 correlates with ascending aortic dilation and acute type A aortic dissection. Gene 851, 147001 (2023).","journal-title":"Gene"},{"key":"18383_CR34","doi-asserted-by":"publisher","first-page":"9494926","DOI":"10.1155\/2022\/9494926","volume":"2022","author":"J-Y Luo","year":"2022","unstructured":"Luo, J.-Y. et al. NFKB1 gene mutant was associated with prognosis of coronary artery disease and exacerbated endothelial mitochondrial fission and dysfunction. Oxid. Med. Cell. Longev. 2022, 9494926 (2022).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"18383_CR35","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41556-020-00588-4","volume":"22","author":"A Aharonov","year":"2020","unstructured":"Aharonov, A. et al. ERBB2 drives YAP activation and EMT-like processes during cardiac regeneration. Nat. Cell Biol. 22, 1346\u20131356 (2020).","journal-title":"Nat. Cell Biol."},{"key":"18383_CR36","first-page":"3547","volume":"18","author":"Z Zhang","year":"2018","unstructured":"Zhang, Z., Yao, L., Yang, J., Wang, Z. & Du, G. PI3K\/Akt and HIF-1 signaling pathway in hypoxia-ischemia (Review). Mol. Med. Rep. 18, 3547\u20133554 (2018).","journal-title":"Mol. Med. Rep."},{"key":"18383_CR37","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. & Gianni, L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56, 185\u2013229 (2004).","journal-title":"Pharmacol. Rev."},{"key":"18383_CR38","doi-asserted-by":"publisher","first-page":"26879","DOI":"10.1074\/jbc.M113.492280","volume":"288","author":"A Ahsan","year":"2013","unstructured":"Ahsan, A. et al. Destabilization of the epidermal growth factor receptor (EGFR) by a peptide that inhibits EGFR binding to heat shock protein 90 and receptor dimerization. J. Biol. Chem. 288, 26879\u201326886 (2013).","journal-title":"J. Biol. Chem."},{"key":"18383_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2019.100942","volume":"54","author":"L F\u00e3o","year":"2019","unstructured":"F\u00e3o, L., Mota, S. I. & Rego, A. C. Shaping the Nrf2-ARE-related pathways in Alzheimer\u2019s and Parkinson\u2019s diseases. Ageing Res. Rev. 54, 100942 (2019).","journal-title":"Ageing Res. Rev."},{"key":"18383_CR40","doi-asserted-by":"publisher","first-page":"2150394","DOI":"10.1155\/2019\/2150394","volume":"2019","author":"Y-Z Wu","year":"2019","unstructured":"Wu, Y.-Z., Zhang, L., Wu, Z.-X., Shan, T.-T. & Xiong, C. Berberine ameliorates doxorubicin-induced cardiotoxicity via a SIRT1\/p66Shc-Mediated Pathway. Oxid. Med. Cell. Longev. 2019, 2150394 (2019).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"18383_CR41","doi-asserted-by":"publisher","first-page":"12283","DOI":"10.1038\/s41598-017-12060-9","volume":"7","author":"LB Priya","year":"2017","unstructured":"Priya, L. B., Baskaran, R., Huang, C.-Y. & Padma, V. V. Neferine ameliorates cardiomyoblast apoptosis induced by doxorubicin: possible role in modulating NADPH oxidase\/ROS-mediated NF\u03baB redox signaling cascade. Sci. Rep. 7, 12283 (2017).","journal-title":"Sci. Rep."},{"key":"18383_CR42","first-page":"4151","volume":"22","author":"D Cheng","year":"2020","unstructured":"Cheng, D. et al. Protective effects of valsartan administration on doxorubicin-induced myocardial injury in rats and the role of oxidative stress and NOX2\/NOX4 signaling. Mol. Med. Rep. 22, 4151\u20134162 (2020).","journal-title":"Mol. Med. Rep."},{"key":"18383_CR43","doi-asserted-by":"publisher","first-page":"e132747","DOI":"10.1172\/jci.insight.132747","volume":"5","author":"T Tadokoro","year":"2020","unstructured":"Tadokoro, T. et al. Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity. JCI Insight 5, e132747 (2020).","journal-title":"JCI Insight"},{"key":"18383_CR44","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1172\/JCI72931","volume":"124","author":"Y Ichikawa","year":"2014","unstructured":"Ichikawa, Y. et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J. Clin. Invest. 124, 617\u2013630 (2014).","journal-title":"J. Clin. Invest."},{"key":"18383_CR45","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s12012-020-09576-4","volume":"20","author":"S Wei","year":"2020","unstructured":"Wei, S. et al. Involvement of ROS\/NLRP3 inflammasome signaling pathway in doxorubicin-induced cardiotoxicity. Cardiovasc. Toxicol. 20, 507\u2013519 (2020).","journal-title":"Cardiovasc. Toxicol."},{"key":"18383_CR46","first-page":"554","volume":"25","author":"E Taskin","year":"2020","unstructured":"Taskin, E. et al. Silencing HMGB1 expression inhibits adriamycin\u2019s heart toxicity via TLR4 dependent manner through MAPK signal transduction. J. BUON Off. J. Balk. Union Oncol. 25, 554\u2013565 (2020).","journal-title":"J. BUON Off. J. Balk. Union Oncol."},{"key":"18383_CR47","first-page":"93","volume":"39","author":"X Wang","year":"2020","unstructured":"Wang, X. et al. TFEB-NF-\u03baB inflammatory signaling axis: A novel therapeutic pathway of dihydrotanshinone I in doxorubicin-induced cardiotoxicity. J. Exp. Clin. Cancer Res. CR 39, 93 (2020).","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"18383_CR48","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.trecan.2016.10.016","volume":"2","author":"L Schito","year":"2016","unstructured":"Schito, L. & Semenza, G. L. Hypoxia-inducible factors: master regulators of cancer progression. Trends Cancer 2, 758\u2013770 (2016).","journal-title":"Trends Cancer"},{"key":"18383_CR49","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jjcc.2022.09.002","volume":"81","author":"T Sato","year":"2023","unstructured":"Sato, T. & Takeda, N. The roles of HIF-1\u03b1 signaling in cardiovascular diseases. J. Cardiol. 81, 202\u2013208 (2023).","journal-title":"J. Cardiol."},{"key":"18383_CR50","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1038\/s41388-020-1201-z","volume":"39","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1\u03b1 with echinomycin. Oncogene 39, 3015\u20133027 (2020).","journal-title":"Oncogene"},{"key":"18383_CR51","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","volume":"22","author":"Y Noguchi","year":"2021","unstructured":"Noguchi, Y., Tachi, T. & Teramachi, H. Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief. Bioinform. 22, bbab347 (2021).","journal-title":"Brief. Bioinform."},{"key":"18383_CR52","doi-asserted-by":"publisher","first-page":"D1516","DOI":"10.1093\/nar\/gkae1059","volume":"53","author":"S Kim","year":"2025","unstructured":"Kim, S. et al. PubChem 2025 update. Nucleic Acids Res. 53, D1516\u2013D1525 (2025).","journal-title":"Nucleic Acids Res."},{"key":"18383_CR53","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s42004-024-01179-2","volume":"7","author":"A Daina","year":"2024","unstructured":"Daina, A. & Zoete, V. Testing the predictive power of reverse screening to infer drug targets, with the help of machine learning. Commun. Chem. 7, 105 (2024).","journal-title":"Commun. Chem."},{"key":"18383_CR54","doi-asserted-by":"publisher","first-page":"W26","DOI":"10.1093\/nar\/gku477","volume":"42","author":"J Nickel","year":"2014","unstructured":"Nickel, J. et al. SuperPred: Update on drug classification and target prediction. Nucleic Acids Res. 42, W26-31 (2014).","journal-title":"Nucleic Acids Res."},{"key":"18383_CR55","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk, D. et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607\u2013D613 (2019).","journal-title":"Nucleic Acids Res."},{"key":"18383_CR56","doi-asserted-by":"publisher","first-page":"D457","DOI":"10.1093\/nar\/gkv1070","volume":"44","author":"M Kanehisa","year":"2016","unstructured":"Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 44, D457\u2013D462 (2016).","journal-title":"Nucleic Acids Res."},{"key":"18383_CR57","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"18383_CR58","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523 (2019).","journal-title":"Nat. Commun."},{"key":"18383_CR59","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.3390\/ijms22073612","volume":"22","author":"P Zeng","year":"2021","unstructured":"Zeng, P., Wang, X.-M., Ye, C.-Y., Su, H.-F. & Tian, Q. The main alkaloids in uncaria rhynchophylla and their anti-alzheimer\u2019s disease mechanism determined by a network pharmacology approach. Int. J. Mol. Sci. 22, 3612 (2021).","journal-title":"Int. J. Mol. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18383-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18383-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18383-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T12:06:34Z","timestamp":1758888394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18383-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["18383"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-18383-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6849752\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33278"}}